IL17A and pancreatic serous cystadenoma: It has been recently proposed that the transition of PsC to PsA occurs through clinically quiescent phases and more importantly, the possible beneficial role of Interleukin 17A inhibition in PsC patients with subclinical inflammatory changes have also been shown.18,19 Most of these studies compared either PsA or PsC patients with healthy controls.